DiscoverNew Retina Radio by EyetubeGA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?
GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?

GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?

Update: 2024-10-281
Share

Description

We finally have two FDA-approved treatments for geographic atrophy (GA)—and yet, many retina specialists have been reluctant to embrace them. Join moderator John Kitchens, MD, as he explores this question with Miguel Busquets, MD, and Esther Kim, MD. Further in the episode, they gameplan patient conversations centered around choosing a treatment, ask how heavily to weigh safety when selecting a complement inhibitor, and preview the GA pipeline.

Comments 
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?

GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?

Retina Today

We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and our services, you agree to our use of cookies as described in our Cookie Policy.